skip to main content
Give

George Udeani

George Udeani
George Udeani, PharmD, DSc, FCP, FCCP

Clinical Professor of Pharmacy Practice

Contact

Texas A&M Irma Lerma Rangel School of Pharmacy
1010 W. Ave. B
Kingsville, TX 78363
udeani@tamu.edu
Phone: 361.221.0701
Fax: 361.221.0798

Education and Training

  • Warnborough College, Ireland, Doctor of Science, Cancer Research, 2006
  • National Cancer Institute – National Institutes of Health, Bethesda, MD, Postdoctoral Training, 1994-2000
  • University of Minnesota, PharmD, 1985

Professional Certifications

  • Fellow, American College of Chest Physicians, 2013
  • Fellow, American College of Clinical Pharmacology, 1996

Research Interests

  • Cancer research
  • Drug discovery and development
  • Pharmacokinetics and pharmacodynamics
  • Pharmaceutical care

Teaching Interests

  • Hematology-Oncology
  • Critical Care
  • Infectious disease
  • Pharmacokinetics and pharmacodynamics

Representative Publications

Andrew R DiNardo, Moshe Arditi, Ashish M Kamat, Kent J Koster, Santiago Carrero, Tomoki Nishiguchi, Maxim Lebedev, Aaron B Benjamin, Pablo Avalos, Marisa Lozano, Madeleine G Moule, Brittany McCune, Baysia Herron, Malik Ladki, Daanish Sheikh, Matthew Spears, Ivan A Herrejon, Courtney Dodge, Sathish Kumar, Robert W Hutchison, Theresa U Ofili, Lynne A Opperman, Jessica A Bernard, Seth P Lerner, George Udeani, Gabriel Neal, Mihai G Netea, Jeffrey D Cirillo. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials 24, 636 (2023). https://doi.org/10.1186/s13063-023-07662-w.

Silva P, Janjan N, Ramos KS, Udeani G, Zhong L, Ory MG, Smith ML. External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations. Frontiers in Medicine. 2023;10.

Ngo H, Mbadugha UJ, Cepeda F, Surani S, Udeani G. Clinical and Economic Impact of Rapid Blood Pathogen Identification Via Verigene. Cureus. 2022 Oct 16;14(10).

Silva P, Jacobs D, Kriak J, Abu-Baker A, Udeani G, Neal G, Ramos K. Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting. Journal of Personalized Medicine. 2021 Jun;11(6):443.

Kumar N, Surani S, Udeani G, Mathew S, John S, Sajan S, Mishra J. Drug-induced liver injury and prospect of cytokine based therapy; A focus on IL-2 based therapies. Life Sciences. 2021 May 1:119544.

Panahi L, Udeani G, Horseman M, Weston J, Samuel N, Joseph M, Mora A, Bazan D. Review of medical therapies for the management of pulmonary embolism. Medicina. 2021 Feb;57(2):110.

Patel PH, Nguyen M, Rodriguez R, Surani S, Udeani G. Omecamtiv Mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management. Cureus. 2021 Jan;13(1).</li> Mbadugha UJ, Surani S, Akuffo N, Udeani G. Antimicrobial therapy for pneumonia or fluid overload?. Cureus. 2021 Jan;13(1).

Kalani C, Awudi E, Alexander T, Udeani G, Surani S. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Hospital Practice. 2019 Aug 8;47(4):181-5.

Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug design, development and therapy. 2017;11:3559.

Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hospital Practice. 2015 Jul 3;43(3):144-9.

Udeani G, Evans J, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients. Hospital Practice. 2014 Aug 1;42(3):109-15.

Evans JD, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients. Postgraduate medicine. 2014 Sep 1;126(5):128-34.

Ramani A, Udeani G, Evans J, Jandourek A, Cole P, Smith A, David Friedland H. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. Journal of Chemotherapy. 2014 Aug 1;26(4):229-34.

Shin YG, Udeani GO, Kosmeder JW, Zhao GM, Dagar S, Onyuksel H, Moriarty RM, Cordell GA, Moon RC, Kinghorn AD, Pezzuto JM. Identification of degradation product of deguelin and its stability using liquid chromatography and electrospray/mass spectrometry. Journal of liquid chromatography &amp; related technologies. 2004 Jan 1;27(6):1057-69.

Udeani GO, Zhao GM, Shin YG, Kosmeder Ii JW, Beecher CW, Kinghorn AD, Moriarty RM, Moon RC, Pezzuto JM. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Cancer chemotherapy and pharmacology. 2001 Mar 1;47(3):263-8.

Udeani GO, Zhao GM, Geun Shin Y, Cooke BP, Graham J, Beecher CW, Kinghorn AD, Pezzuto JM. Pharmacokinetics and tissue distribution of betulinic acid in CD‐1 mice Biopharmaceutics &amp; drug disposition. 1999 Nov;20(8):379-83.

Udeani GO, Gerhäuser C, Thomas CF, Moon RC, Kosmeder JW, Kinghorn AD, Moriarty RM, Pezzuto JM. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer research. 1997 Aug 15;57(16):3424-8.

Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997 Jan 10;275(5297):218-20.